BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 28
• 29
• 30

• Biotech Bay

  OrbusNeich Release: Three-Year Clinical Outcomes from Use of Genous(TM) Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy

  November 8, 2011

   · 

  3 min read
• Biotech Beach

  Breaking Study: ICU Medical, Inc. ChemoClave(R) System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs

  November 8, 2011

   · 

  4 min read
• Drug Development

  Boehringer Ingelheim Pharmaceuticals, Inc. Release: Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types

  November 8, 2011

   · 

  6 min read
• Drug Development

  Outstanding Interim Results of Stentys International Clinical Study of 600 Heart Attack Patients

  November 8, 2011

   · 

  1 min read
• Drug Development

  Cytheris SA Announces Interim Results from ECLIPSE 2 Hepatitis C Multicenter Study of IL-7 in Chronically Infected Genotype 1 and 4 Nonresponders to Standard of Care (SOC)

  November 8, 2011

   · 

  1 min read
• BioMidwest

  Adeona Pharmaceuticals Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting

  November 8, 2011

   · 

  4 min read
• Drug Development

  12-Week On-Treatment Results from Large Phase IIb Study (COMMAND-1) of Bristol-Myers Squibb Company’s NS5A Inhibitor Daclatasvir Support Anti-HCV Activity and Safety Profile Observed in Earlier Studies

  November 8, 2011

   · 

  1 min read
• Pharm Country

  Covance Inc. to Present at Credit Suisse 2011 Healthcare Conference

  November 8, 2011

   · 

  2 min read
• Drug Development

  Boehringer Ingelheim Pharmaceuticals, Inc. Release: BI 201335 Demonstrates Potential toShorten HCV Treatment Duration While Achieving High Sustained Virological Response Rates in Difficult to Treat Patients

  November 8, 2011

   · 

  1 min read
• Biotech Bay

  Positive Long Term Clinical Data of the Cappella Sideguard® Stent System Announced at TCT 2011

  November 8, 2011

   · 

  1 min read